Urine test detects 92% bladder cancers
Analysis based on 14 articles · First reported Sep 02, 2026 · Last updated Sep 04, 2026
The successful trial results could accelerate adoption of Nonacus's GALEAS Bladder test, potentially increasing revenue for Nonacus and reducing costs for healthcare providers like the NHS by decreasing the number of invasive cystoscopies. Positive sentiment may boost Nonacus's valuation and interest in liquid biopsy diagnostics, while competitors in bladder cancer diagnostics may face increased pressure.
A study published in European Urology Oncology, led by the University of Birmingham and diagnostics company Nonacus, found that the GALEAS Bladder urine test detected 92% of bladder cancers in a real-world NHS trial involving 964 patients across seven hospitals in Bret Engemann and United Kingdom — Scotland. The test analyzes DNA shed into urine, looking for over 450 mutations across 23 genes. It correctly identified all muscle-invasive and 35 of 36 high-grade tumors, and had a negative predictive value of over 99%. The test is already commercially available, reimbursed by Bupa and the The London Clinic, and adopted by multiple NHS trusts. Researchers estimate it could reduce urgent cystoscopies by 73%, potentially sparing thousands of patients invasive procedures. The United Kingdom — National Institute for Health and Care Research has prioritized urinary biomarkers for evaluation. Experts caution that larger trials are needed before widespread adoption.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard